{"id":"W1856900646","doi":"10.1186/s13075-015-0741-z","title":"Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials","year":2015,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"SUNY Downstate Medical Center; University of North Carolina at Chapel Hill; School of Medicine, New York University; York University; Anthera; Amgen; Cedars-Sinai Medical Center; University of Pittsburgh; State University of New York; University of Southern California","keywords":"Medicine; Rheumatology; Internal medicine; Double blind; Antagonist; B-cell activating factor; Randomized controlled trial; Physical therapy; Immunology; Placebo; Alternative medicine; Antibody; Pathology; Receptor; B cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004029308,0.000492558,0.002015706,0.0003271175,0.000563875,0.0001371107,0.0005207651,0.0003995601,0.0001973018],"category_scores_gemma":[0.000302753,0.0002709071,0.000287621,0.0003681938,0.002351749,0.0002148157,0.0001198211,0.0004916529,0.000157866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001153802,"about_ca_system_score_gemma":0.0003623464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002333478,"about_ca_topic_score_gemma":0.0002524373,"domain_scores_codex":[0.9919029,0.0047476,0.001297618,0.0008126726,0.0003339518,0.0009052578],"domain_scores_gemma":[0.9939981,0.003530517,0.0005794684,0.001041217,0.0007098479,0.0001408686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6844164,0.005075336,0.0001860304,0.000008317186,0.001506674,0.00004999623,0.005480571,0.000001238146,0.2503431,0.0001871145,0.002483608,0.05026167],"study_design_scores_gemma":[0.8800197,0.01065195,0.000005255537,0.0001593565,0.0000822716,0.0002222463,0.002128556,0.000006319255,0.08605124,0.0002506191,0.02013558,0.0002869246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9257935,0.06687052,0.0000298922,0.0007983999,0.0006130241,0.004414779,0.0009917634,0.00005885468,0.0004293138],"genre_scores_gemma":[0.966706,0.02987162,0.00003680908,0.00003292407,0.0001248441,0.0005212659,0.001173594,0.00005238815,0.001480564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1956033,"threshold_uncertainty_score":0.9999743,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08287231878034751,"score_gpt":0.3569021099913607,"score_spread":0.2740297912110132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}